title: Epidermal growth factor receptor: is a novel therapeutic target for pancreatic cancer?
abstract: Expression of epidermal growth factor receptors (EGFR) is exaggerated in pancreatic adenocarcinoma and activation of EGFR appears to have an important role in the growth and differentiation of this and in other tumors. Therefore, blockade or inactivation of EGFR by monoclonal antibodies or by tyrosine kinase inhibitors has significant potential as an effective anti-cancer therapy. One of the very recent significant developments in the field of molecular biology involves the use of antisense of EGFR or EGFR gene silencing in pancreatic cancer cells as a potential targeted therapy for patients with pancreatic adenocarcinoma.
authors.affiliation: Cancer Research Unit, Department of Veterans Affairs Medical Center, 4801 East Linwood Boulevard, Kansas City, MO 64128-2226, USA. Animesh.Dhar@med.va.gov <Animesh.Dhar@med.va.gov>
authors.forename: Animesh
authors.initials: A
authors.lastname: Dhar
authors.forename: Smita
authors.initials: S
authors.lastname: Mehta
authors.forename: Snigdha
authors.initials: S
authors.lastname: Banerjee
authors.forename: Kakali
authors.initials: K
authors.lastname: Dhar
authors.forename: Gopal
authors.initials: G
authors.lastname: Dhar
authors.forename: Krishanu
authors.initials: K
authors.lastname: Sengupta
authors.forename: Gibanananda
authors.initials: G
authors.lastname: Ray
authors.forename: Sushanta K
authors.initials: SK
authors.lastname: Banerjee
authors.forename: Donald R
authors.initials: DR
authors.lastname: Campbell
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D004354:Drug Screening Assays, Antitumor; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D066246:ErbB Receptors